Brepocitinib Overview & RVT-3101 Update

RVT-3101 Shows High-End Efficacy Results in TUSCANY-2 Statistically significant and clinically meaningful efficacy results observed at every dose tested and in both overall and biomarker positive populations Overall Population At Expected P3 Dose Biomarker Positive Population* At Expected P3 Dose Clinical Remission Endoscopic Improvement 31% 40% 40% 41% for biologic-experienced 56% 56% for biologic-experienced Well-tolerated with no dose-related trends in AEs and no impact of immunogenicity on clinical efficacy or safety results roivant * A single, prospectively defined biomarker was used in the study and was the same biomarker used in the Phase 2a study 14 For investor audiences only

View entire presentation